Survey: Oncologists Expect To Prescribe Onureg in AML
November 1
With the FDA’s approval last month of Onureg (azacitidine), people with acute myeloid leukemia (AML) now have an oral version of a longtime injectable treatment within that class. Zitter Insights found that more than half of oncologists polled are likely to prescribe the drug as a maintenance treatment for the condition.
On Sept. 1, the FDA approved Bristol-Myers Squibb Co. unit Celgene Corp.’s Onureg, a tablet, for the continued treatment of adults with AML who achieved first complete remission or CR with incomplete blood count recovery following intensive induction chemotherapy and who are not able to complete intensive curative therapy (RSP 9/20, p. 8).
Related Posts
May 11
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed Doses
READ MORE
May 11
New FDA Approvals: FDA Expands Patient Population of Takeda’s HyQvia
READ MORE
May 11
AbbVie Files Lawsuit Against Alternate Funding Company Payer Matrix Alleging ‘Fraudulent and Deceptive Scheme’
READ MORE
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
